CDK9
Cyclin-dependent kinase 9
As of the edition of 20 October 2026, CDK9 (cyclin-dependent kinase 9, UniProt P50750) has 16 drugs tested at it and 19 companies on the list, 14 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P50750
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 28
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Skin and connective tissue; Digestive system; Urinary and reproductive; Inherited and neonatal
- Registered trials of its drugs
- 125
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Went quiet | 3 |
| Stopped | 8 |
| Status not established | 1 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alvocidib | Stopped | Phase 2 | none listed |
| Dinaciclib | Stopped | Phase 3 | none listed |
| Riviciclib | Went quiet | Phase 2 | none listed |
| Seliciclib | Stopped | Phase 2 | none listed |
| Zotiraciclib | Stopped | Phase 2 | none listed |
| Enitociclib | Stopped | Phase 2 | none listed |
| BTX-A51 | Active | Phase 1 | none listed |
| Zemirciclib | Active | Phase 2 | none listed |
| BMS-387032 | Went quiet | Phase 1 | none listed |
| GFH009 | Active | Phase 2 | none listed |
| PRT2527 | Status not established | Phase 1 | none listed |
| BAY1143572 | Went quiet | Phase 1 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 14 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 19 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Sanofi | Route A |
| AbbVie | Route A |
The other 16 companies at CDK9
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at CDK9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.